Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions.

Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, Hauser RA, Olanow WC, Shoulson I, Tandon PK; Parkinson Study Group, Leurgans S.

Mov Disord. 2008 Apr 15;23(5):690-9. doi: 10.1002/mds.21894.

PMID:
18228568
2.
3.

The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.

Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ.

Clin Ther. 2009 Jan;31(1):89-98. doi: 10.1016/j.clinthera.2009.01.012. Erratum in: Clin Ther. 2009 Mar;31(3):677.

PMID:
19243709
4.

Levodopa response in early Parkinson's disease.

Hauser RA, Auinger P, Oakes D; Parkinson Study Group.

Mov Disord. 2009 Dec 15;24(16):2328-36. doi: 10.1002/mds.22759.

PMID:
19908302
5.

Objective changes in motor function during placebo treatment in PD.

Goetz CG, Leurgans S, Raman R, Stebbins GT.

Neurology. 2000 Feb 8;54(3):710-4.

PMID:
10680808
6.

Does levodopa slow or hasten the rate of progression of Parkinson's disease?

Fahn S; Parkinson Study Group.

J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42. Review.

PMID:
16222436
7.

Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses.

Mestre TA, Shah P, Marras C, Tomlinson G, Lang AE.

Neurology. 2014 Apr 22;82(16):1402-9. doi: 10.1212/WNL.0000000000000340. Epub 2014 Mar 21.

8.

Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.

Tompson D, Oliver-Willwong R.

Clin Neuropharmacol. 2009 May-Jun;32(3):140-8. doi: 10.1097/WNF.0B013E318176C505.

PMID:
18978485
9.

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.

Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C.

Mov Disord. 2013 Nov;28(13):1838-46. doi: 10.1002/mds.25561. Epub 2013 Jul 12.

PMID:
23853029
10.

Placebo influences on dyskinesia in Parkinson's disease.

Goetz CG, Laska E, Hicking C, Damier P, Müller T, Nutt J, Warren Olanow C, Rascol O, Russ H.

Mov Disord. 2008 Apr 15;23(5):700-7. doi: 10.1002/mds.21897.

12.

The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.

Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL; PKDS009 Study Group.

CNS Drugs. 2004;18(11):733-46. Erratum in: CNS Drugs. 2005;19(7):633.

PMID:
15330687
13.

Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.

Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.

Int J Clin Pract. 2009 Apr;63(4):613-23. doi: 10.1111/j.1742-1241.2009.02027.x. Epub 2009 Feb 16.

PMID:
19222614
15.

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D.

Lancet Neurol. 2010 Jun;9(6):573-80. doi: 10.1016/S1474-4422(10)70106-X. Epub 2010 May 7.

PMID:
20452823
16.
17.

Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.

Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R; Study 018 Investigators.

Mov Disord. 2014 Sep;29(10):1273-80. doi: 10.1002/mds.25961. Epub 2014 Jul 10.

18.
19.

Bromocriptine versus levodopa in early Parkinson's disease.

Ramaker C, van Hilten JJ.

Cochrane Database Syst Rev. 2000;(3):CD002258. Review. Update in: Cochrane Database Syst Rev. 2007;(4):CD002258.

PMID:
10908538
20.

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.

Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW.

Lancet Neurol. 2011 May;10(5):415-23. doi: 10.1016/S1474-4422(11)70073-4. Epub 2011 Apr 7. Erratum in: Lancet Neurol. 2012 Dec;11(12):1021.

PMID:
21482191
Items per page

Supplemental Content

Write to the Help Desk